Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | GALR3 | O60755 | 1/20 | 0.50 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.50 |
| ▸ | GPR183 | P32249 | 1/20 | 0.50 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 6/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21442501 | 0.88 | RAB9A (0.51) | NPC1RAB9AKMT2AMEN1GALR3 | |
| SCHEMBL15566224 | 0.87 | NPC1 (0.50) | NPC1RAB9AKMT2AMEN1GALR3 | |
| SCHEMBL15596827 | 0.85 | NPC1 (0.44) | NPC1RAB9AKMT2AMEN1GALR3 | |
| SCHEMBL15596824 | 0.83 | RAB9A (0.45) | NPC1RAB9AKMT2AMEN1GALR3 | |
| SCHEMBL15596643 | 0.80 | NPC1 (0.44) | NPC1RAB9AKMT2AMEN1GALR3 | |
| SCHEMBL19147799 | 0.80 | NPC1 (0.44) | NPC1RAB9AKMT2AMEN1GALR3 | |
| SCHEMBL14760853 | 0.77 | SMN1; SMN2 (0.48) | NPC1RAB9AKMT2AMEN1GALR3 | |
| SCHEMBL28014136 | 0.76 | KMT2A (0.45) | NPC1RAB9AKMT2AMEN1GALR3 | |
| SCHEMBL21442571 | 0.73 | SMN1; SMN2 (0.46) | NPC1RAB9AKMT2AMEN1GALR3 | |
| SCHEMBL15596815 | 0.72 | MEN1 (0.38) | NPC1RAB9AKMT2AMEN1GALR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170283-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2025-05-29 | — | — | US | disclosed |
| CN-113754589-B | Compositions, methods, and systems for synthesizing and using contrast agents | 蓝瑟斯医学影像公司 | 2024-09-27 | — | — | CN | disclosed |
| US-11744906-B2 | Compositions, methods, and systems for the synthesis and use of imaging agents | LANTHEUS MEDICAL IMAGING, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11744906-B2 | Compositions, methods, and systems for the synthesis and use of imaging agents | LANTHEUS MEDICAL IMAGING, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11744906-B2 | Compositions, methods, and systems for the synthesis and use of imaging agents | LANTHEUS MEDICAL IMAGING, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| CN-113754589-A | Compositions, methods, and systems for synthesis and use of contrast agents | 蓝瑟斯医学影像公司 | 2021-12-07 | — | — | CN | disclosed |
| CN-107311935-B | Compositions, methods, and systems for synthesis and use of contrast agents | 蓝瑟斯医学影像公司 | 2021-10-08 | — | — | CN | disclosed |
| US-20200230264-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2020-07-23 | — | — | US | disclosed |
| US-20200230264-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2020-07-23 | — | — | US | disclosed |
| EP-3653621-A1 | APPARATUS FOR SYNTHESIZING THE IMAGING AGENT 4-CHLORO-2-(1,1-DIMETHYLETHYL)-5-[[4-[[2-(FLUORO-[18F])ETHOXY]METHYL]PHENYL]METHOXY]-3(2H)-PYRIDAZINONE (FLUORPIRIDAZ [18F]) | Lantheus Medical Imaging, Inc. (US) | 2020-05-20 | — | — | EP | disclosed |
| US-20170151353-A9 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2017-06-01 | — | — | US | disclosed |
| US-9555138-B2 | — | — | 2017-01-31 | — | — | US | disclosed |
| US-9555138-B2 | — | — | 2017-01-31 | — | — | US | disclosed |
| US-9555138-B2 | — | — | 2017-01-31 | — | — | US | disclosed |
| US-20150196672-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2015-07-16 | — | — | US | disclosed |
| US-20150196672-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2015-07-16 | — | — | US | disclosed |
| US-20150196672-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2015-07-16 | — | — | US | disclosed |
| EP-2882719-A2 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | Lantheus Medical Imaging, Inc. (US) | 2015-06-17 | — | — | EP | disclosed |
| WO-2014026079-A2 | COMPOSITIONS, METHODS, AND SYSTEMS OF THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2014-02-13 | — | — | WO | disclosed |
| WO-2014026079-A2 | COMPOSITIONS, METHODS, AND SYSTEMS OF THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2014-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150196672-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | TNNI3, FABP3, TNNT2 | NPC1 272/4885RAB9A 2222/4885KMT2A 4131/4885 |
| US-20250170283-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | FABP3, TNNI3, TNNT2 | NPC1 221/4885RAB9A 2539/4885KMT2A 4341/4885 |
| US-20170151353-A9 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | TNNI3, FABP3, TNNT2 | NPC1 272/4885RAB9A 2222/4885KMT2A 4131/4885 |
| US-20200230264-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | FABP3, TNNI3, TNNT2 | NPC1 221/4885RAB9A 2539/4885KMT2A 4341/4885 |
| US-11744906-B2 | Compositions, methods, and systems for the synthesis and use of imaging agents | FABP3, TNNI3, TNNT2 | NPC1 221/4885RAB9A 2539/4885KMT2A 4341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.